Streetbeat News

Equity Actions

TNXP

Tonix Pharmaceuticals Holding shares are trading lower after the company announced the pricing of an approximately $4 million public offering of 7,060,918 shares at $0.57 per share.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 12:38 pm

TNXP

Tonix Pharmaceuticals has announced a public offering of approximately $4 million, selling 7,060,918 shares at $0.57 per share.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 12:37 pm

CASI

MEDS

RXRX

Market-Moving News for June 27th includes significant updates from CASI Pharmaceuticals, TRxADE HEALTH, and Recursion Pharmaceuticals. CASI plans to submit a CID-103 IND application and received a non-binding proposal to acquire its China business for $40M. TRxADE HEALTH shares are up following their Q1 financial results. Recursion Pharmaceuticals announced the pricing of its public offering of 30,769,230 shares at $6.50 per share, leading to a drop in share price.

Portfolio Pulse from ryanfaloona@benzinga.com

June 27, 2024 | 12:37 pm

TRNR

Interactive Strength has filed for an offer of up to 3.57 million shares of common stock, along with Series A-1 and A-2 warrants.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 12:22 pm

GRI

GRI Bio, Inc. (NASDAQ:GRI) announced the pricing of a $4M public offering, including Series C-1 and C-2 warrants. If fully exercised, the warrants could bring in an additional $8M. The offering is expected to close around June 28, 2024, with H.C. Wainwright & Co. as the exclusive placement agent.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 12:20 pm

NYCB

New York Community Bancorp (NYSE: NYCB) has announced a 1-for-3 reverse stock split, expected to become effective in mid-to-late July. This decision was approved by shareholders at the annual meeting on June 5th.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 12:15 pm

HUBC

Hub Security has restructured $8M of its debt due this month and secured an additional $2M in debt financing. Key shareholders exercised warrants at $0.90 per share, adding $5M in capital.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 12:13 pm

DARE

Daré Bioscience (NASDAQ:DARE) announced a 1-for-12 reverse stock split effective July 1, 2024. The stock will trade on a split-adjusted basis starting that day under the same symbol, DARE.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 12:12 pm

TRML

Tourmaline Bio has appointed Ryan Robinson as the new Chief Financial Officer, effective June 25.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 12:06 pm

IPA

ImmunoPrecise Antibodies has appointed Kristin Taylor as the Chief Financial Officer, transitioning her from the interim CFO role to a permanent position effective immediately.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 12:05 pm